BUZZ-Capricor 因杜兴氏肌肉萎缩症相关细胞疗法获得 FDA 优先审查而上涨

路透中文
04 Mar
BUZZ-Capricor 因杜兴氏肌肉萎缩症相关细胞疗法获得 FDA 优先审查而上涨

3月4日 - ** Capricor Therapeutics CAPR.O股价盘前上涨约12%至15.30美元

*Capricor TherapeuticsCAPR.O股价盘前上涨约12%至15.30美元 * Capricor TherapeuticsCAPR.O称美国FDA已授予其治疗杜兴氏肌肉萎缩症相关心脏疾病的药物优先审评权(DMD)

** DMD心肌病是一种心肌疾病,可在遗传病患者身上发生,导致进行性肌无力。

** 美国食品和药物管理局将于8月31日前就细胞疗法deramiocel作出决定

** 优先审查 "资格将审查时间缩短为自申请之时起的六个月,而标准审查时间为 10 个月

** 截至上次收盘,股价在过去 12 个月中上涨了近三倍

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10